Filed with ASX · · 2 pages · English
Arovella Therapeutics Limited has appointed Dr. Nicole Van Der Weerden as the Acting Chief Executive Officer, effective immediately. The Chairman expressed confidence in her leadership and the company's recent achievements in clinical development. Dr. Van Der Weerden's compensation includes a salary and potential bonuses based on performance.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
ASX: ALA Arovella Therapeutics Limited ACN 090 987 250 ASX Release 4 November 2026 DR NICOLE VAN DER WEERDEN APPOINTED CEO The Company has appointed Dr Nicole Van Der Weerden as Acting Chief Executive Officer effective today. “Arovella is now a clinical stage company and I am proud to be leading...
Arovella Therapeutics Limited on 6ix
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics